IGF1 and acromegaly: In conclusion, this observational, multicenter study for the evaluation of the response to PEGV treatment in 75 patients with acromegaly in Argentina demonstrates that PEGV is an effective and safe drug for the treatment of uncontrolled acromegaly, with IGF-1 normalization rates similar to those reported in the international literature.